A study on thyroid cancer, detecting circulating tumor cells and BRAF gene mutations through preoperative blood tests, and comparing the identified BRAF gene mutations to postoperative pathological tissue BRAF gene mutations
Not Applicable
- Conditions
- Neoplasms
- Registration Number
- KCT0005820
- Lead Sponsor
- Seoul National University Bundang Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Patients over 20 years of age
Patients who agree to the study and undergo thyroidectomy for thyroid cancer
Exclusion Criteria
Patients with diseases other than the thyroid gland
Patients who cannot communicate
Patients who refused the study
Patients with non-thyroid papillary cancer on postoperative biopsy
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The BRAF mutation observed in circulatory tumor cells was compared with the final pathological tissue BRAF mutation. About 70-80% of BRAF mutations were observed in the final pathologic examination of thyroid cancer in Korean patients. At this time, it was confirmed that the BRAF mutation of circulating tumor cells was also observed in 70-80%. In addition, it was confirmed that BRAF mutations were observed simultaneously in each
- Secondary Outcome Measures
Name Time Method The relevance of thyroid cancer by stage. In general, BRAF mutations are observed as the stage of thyroid cancer increases. In other words, we want to confirm whether there is a relationship between the BRAF mutation in circulatory tumor cells and the stage of thyroid cancer.